Finland· FI-REL-REL1279
Duocort
A hydrocortison butyrat und antiseptika product containing hydrocortisone butyrate + chlorhexidine digluconate solution 20 %, registered in Finland by Orion Corporation.
Checked against Fimea (Finland) on
Informational only — not a medical device.
The record
At a glance
Fimea (Finland)- Active substance
- Hydrocortisone butyrate + Chlorhexidine digluconate solution 20 %
- Manufacturer
- Orion Corporation
- Country
- Finland (FI)
- ATC code
- D07BB04
- ATC class
- Hydrocortison Butyrat und Antiseptika
- Reimbursed
- Not published by this register
- Source register
- Fimea (Finland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under D07BB04
Hydrocortison butyrat und antiseptika, as other registers publish it.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Fimea (Finland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/c2e404ca-5533-420f-9485-5eb8e36a6dc8 GET /v1/drugs/c2e404ca-5533-420f-9485-5eb8e36a6dc8?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"ddd": null,
"form": "emulsiovoide",
"route": "Iholle",
"ddd_unit": null,
"strength": "1 mg/g + 10 mg/g",
"atc_label": "hydrokortisonibutyraatti ja antiseptit",
"ma_number": "11533",
"auth_status": "Myyntilupa myönnetty",
"eu_ma_number": null,
"fimea_rel_id": "REL1279",
"authorised_at": "1994-08-15"
}See everything about hydrocortison butyrat und antiseptika.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.